Roche's Breast-Cancer Miss Surprises After Two Positive Trials -- Market Talk

Dow Jones03-09

0822 GMT - News that Roche's breast-cancer drug giredestrant didn't meet the primary objective of a late-stage study for breast cancer came as a surprise after two earlier studies for the same drug showed positive results, Vontobel's Stefan Schneider says in a research note. Vontobel says it estimated 2 billion Swiss francs in peak sales for the indication covered by the trial, with an 80% probability of success. This was the first of two phase 3 studies for giredestrant as a first-line treatment for breast cancer. Vontobel removes expected sales from the two from its models as it awaits results from the other trial, due next year, the analyst says. Vontobel also reduces its target price for the Swiss drugmaker to 346 francs from 356 francs. Shares fall 5.4% to 322.70 francs. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

March 09, 2026 04:23 ET (08:23 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2618468186?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-09 16:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618468186","market":"us","top_or_hot":-1,"title":"Roche's Breast-Cancer Miss Surprises After Two Positive Trials -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0822 GMT - News that Roche's breast-cancer drug giredestrant didn't meet the primary objective of a late-stage study for breast cancer came as a surprise after two earlier studies for the same drug showed positive results, Vontobel's Stefan Schneider says in a research note. Vontobel says it estimated 2 billion Swiss francs in peak sales for the indication covered by the trial, with an 80% probability of success. This was the first of two phase 3 studies for giredestrant as a first-line treatment for breast cancer. Vontobel removes expected sales from the two from its models as it awaits results from the other trial, due next year, the analyst says. Vontobel also reduces its target price for the Swiss drugmaker to 346 francs from 356 francs. Shares fall 5.4% to 322.70 francs. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 09, 2026 04:23 ET (08:23 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roche's Breast-Cancer Miss Surprises After Two Positive Trials -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoche's Breast-Cancer Miss Surprises After Two Positive Trials -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-03-09 16:23</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0822 GMT - News that Roche's breast-cancer drug giredestrant didn't meet the primary objective of a late-stage study for breast cancer came as a surprise after two earlier studies for the same drug showed positive results, Vontobel's Stefan Schneider says in a research note. Vontobel says it estimated 2 billion Swiss francs in peak sales for the indication covered by the trial, with an 80% probability of success. This was the first of two phase 3 studies for giredestrant as a first-line treatment for breast cancer. Vontobel removes expected sales from the two from its models as it awaits results from the other trial, due next year, the analyst says. Vontobel also reduces its target price for the Swiss drugmaker to 346 francs from 356 francs. Shares fall 5.4% to 322.70 francs. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 09, 2026 04:23 ET (08:23 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RHHBY","symbol_name":"罗氏控股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2618468186","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618468186","pubTimestamp":1773044580,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0822 GMT - News that Roche's breast-cancer drug giredestrant didn't meet the primary objective of a late-stage study for breast cancer came as a surprise after two earlier studies for the same drug showed positive results, Vontobel's Stefan Schneider says in a research note. Vontobel says it estimated 2 billion Swiss francs in peak sales for the indication covered by the trial, with an 80% probability of success. This was the first of two phase 3 studies for giredestrant as a first-line treatment for breast cancer. Vontobel removes expected sales from the two from its models as it awaits results from the other trial, due next year, the analyst says. Vontobel also reduces its target price for the Swiss drugmaker to 346 francs from 356 francs. Shares fall 5.4% to 322.70 francs. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RHHBY":"罗氏控股","03165":"华夏欧优股对冲","BK4007":"制药"},"translate_title":"罗氏乳腺癌在两次积极试验后未能获得惊喜——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RHHBY":0.9,"03165":0.6},"content_text":"0822 GMT - News that Roche's breast-cancer drug giredestrant didn't meet the primary objective of a late-stage study for breast cancer came as a surprise after two earlier studies for the same drug showed positive results, Vontobel's Stefan Schneider says in a research note. Vontobel says it estimated 2 billion Swiss francs in peak sales for the indication covered by the trial, with an 80% probability of success. This was the first of two phase 3 studies for giredestrant as a first-line treatment for breast cancer. Vontobel removes expected sales from the two from its models as it awaits results from the other trial, due next year, the analyst says. Vontobel also reduces its target price for the Swiss drugmaker to 346 francs from 356 francs. Shares fall 5.4% to 322.70 francs. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 09, 2026 04:23 ET (08:23 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618468186","isCrawlerRequest":true}